Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax plus azacitidine maintenance after first remission in acute myeloid leukemia
CTR20200158Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Jun 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of venetoclax, azacitidine, CC-486 in acute myeloid leukemia (AML), sponsored by AbbVie Inc.. Started Jun 2021; status: completed.
02
Drugs
venetoclaxazacitidineCC-486
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on CTR20200158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200158.